newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

  • IGC Pharma activated a new Phase 2 CALMA trial site at Tandem Clinical Research in Metairie, Louisiana, to evaluate IGC-AD1 for agitation in Alzheimer's dementia.
  • The site is located at 3901 Houma Blvd., Suite 500, Metairie, LA 70006, & led by Principal Investigator Dr. Angela Traylor, a neurologist & psychiatrist.
  • CEO Ram Mukunda stated that enrollment is over 70% complete & the new site enhances geographic reach & patient access.
  • IGC Pharma leverages AI to develop treatments for Alzheimer's & metabolic disorders, with a pipeline including IGC-AD1, TGR-63, & programs targeting tau proteins & neurodegeneration.
  • The press release includes forward-looking statements regarding risks such as regulatory approval, AI algorithm performance, & economic conditions.